Abandon Import Supply
Another step towards that goal has been made by Russian pharmaceutical industry by opening at Medsintez (Sverdlovsk region) a microbiological facility implementing a full cycle of genetically engineered human insulin production – from substance to finished pharmaceutical form.
Currently the plant manufactures finished forms of genetically engineered insulin and covers 15 per cent of the Russian insulin market. In the second quarter of this year Medsintez is planning to complete registration of own substance of insulin, its test batches were released in 2015. Industrial-scale production will begin in Q4 2016. Own substance will provide independence of production from expensive import: one kilogram of foreign product costs about 80 thos. euro. The new facility is trying to make its products both of high quality and accessible for consumers. After passing to the full cycle production Medsintez is planning to manufacture insulin at an end price for consumer of 300 to 400 rubles.
Please note, that full cycle production of insulin does not only imply contribution into development of local pharma, but will ensure safety of the country on the whole.